Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Sponsor: SecuraBio
Terminated
Sponsor is focusing on studies which can enable registration of duvelisib
Other terminated trials from SecuraBio
This PHASE3 trial investigates Follicular Lymphoma and is currently terminated or withdrawn. SecuraBio leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Apr 2021 — Oct 2023 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Terminated PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
May 2017 — Sep 2017 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SecuraBio
For direct contact, visit the study record on ClinicalTrials.gov .